Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 7814-7824
DOI: 10.1111/dom.70920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.06.2026. Verfasst von Atte Vaden und 7 weiteren Autor:innen. Beteiligte Einrichtung: West-Northern Central Hospital, Department of Internal Medicine, Kemi, Finland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Pharma.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland. Materials and Methods Adults living with T2D ( n = 7249) who initiated oral semaglutide between April 1, 2021, and December 31, 2023, were identified from national registers and followed until June 30, 2024. Primary endpoints were changes in HbA1c and body weight from baseline to 182.5 and 365 days. Secondary endpoints included changes in LDL‐cholesterol, HDL‐cholesterol, total cholesterol, triglycerides, HDL/triglycerides ratio, and ALT.
Results
Of those initiating oral semaglutide, 65.8% remained on treatment at 180 days and 55.2% at 365 days. Among patients included in longitudinal trajectory modelling, mean HbA1c ( n = 2784) decreased from 7.9% to 6.8% at 182.5 days (95% CI: −1.20 to −1.04; p < 0.001) and to 6.9% at 365 days (95% CI: −1.18 to −0.95; p < 0.001). Mean body weight ( n = 832) declined from 106 to 100 kg at 182.5 days (95% CI: −7 to −5; p < 0.001) and to 98 kg at 365 days (95% CI: −10 to −6; p < 0.001). LDL‐cholesterol ( n = 1402), and triglycerides ( n = 975) were significantly reduced at 182.5 days with little further change at 365 days. Mean ALT ( n = 1762) declined from 50 to 42 U/L at 182.5 days (95% CI: −10 to −6, p < 0.001) and to 37 U/L at 365 days (; 95% CI: −16 to −10; p < 0.001). While weight at baseline was lower at patients aged at least 75 years, the changes in HbA1c and weight were similar compared to patients under 75 years of age.
Conclusion
Oral semaglutide significantly improves glycaemic and lipid control, body weight, and liver enzymes in adults living with T2D treated in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West-Northern Central Hospital, Department of Internal Medicine, Kemi, Finland.
- Tesoma Welfare Alliance, Tampere, Finland.
- Medical Center Mehiläinen, Tampere, Finland.
- Nordic Healthcare Group, Helsinki, Finland.
- Novo Nordisk Farma Oy, Espoo, Finland.
- Faculty of Social Sciences, Health Sciences, Epidemiology, Tampere University, Tampere, Finland.
ORCID-Profile: Eija Heikkilä
Förderung
- Novo Nordisk Pharma
Zitieren
APA
Vaden, A., Lahelma, M., Nurmi, L., Heikkilä, E., Vessari, H., Luoto, H., Saukkonen, T., & Niskanen, L. (2026). Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland. Diabetes, Obesity and Metabolism, 28(9), 7814-7824. https://doi.org/10.1111/dom.70920
Vancouver
Vaden A, Lahelma M, Nurmi L, Heikkilä E, Vessari H, Luoto H, et al. Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland. Diabetes, Obesity and Metabolism. 2026;28(9):7814-7824. doi:10.1111/dom.70920
BibTeX
@article{Vaden2026,
author = {Vaden, Atte and Lahelma, Mari and Nurmi, Lalli and Heikkilä, Eija and Vessari, Hannu and Luoto, Hanne and Saukkonen, Tero and Niskanen, Leo},
title = {Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {7814--7824},
doi = {10.1111/dom.70920}
}
EUVIMED